Taro Pharmaceutical Industries Ltd (TARO)
42.33
+0.07
(+0.17%)
USD |
NYSE |
Mar 28, 16:00
42.33
0.00 (0.00%)
After-Hours: 17:16
Price Chart
Key Stats
Price and Performance | |
---|---|
Market Cap | 1.591B |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | 75.06% |
Valuation | |
PE Ratio | 34.70 |
PE Ratio (Forward) | Upgrade |
PS Ratio | 2.605 |
Price to Book Value | 0.8943 |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | -- |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | 0.00 |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | 78.88% |
Profile
Taro Pharmaceutical Industries Ltd produces, researches, develops, and markets pharmaceutical products. Its primary focus includes semi-solid formulations, such as creams and ointments, and other dosage forms such as liquids, capsules, and tablets. The company is engaged in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories. Geographically, it derives a majority of its revenue from the United States and also has a presence in Canada, Israel, and Other Countries. |
URL | https://www.taro.com |
Investor Relations URL | https://taro.gcs-web.com |
HQ State/Province | N/A |
Sector | Healthcare |
Industry | Drug Manufacturers - Specialty & Generic |
Equity Style | Small Cap/Blend |
Next Earnings Release | May. 23, 2024 (est.) |
Last Earnings Release | Jan. 25, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | Dec. 10, 2018 |
Ratings
Profile
Taro Pharmaceutical Industries Ltd produces, researches, develops, and markets pharmaceutical products. Its primary focus includes semi-solid formulations, such as creams and ointments, and other dosage forms such as liquids, capsules, and tablets. The company is engaged in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories. Geographically, it derives a majority of its revenue from the United States and also has a presence in Canada, Israel, and Other Countries. |
URL | https://www.taro.com |
Investor Relations URL | https://taro.gcs-web.com |
HQ State/Province | N/A |
Sector | Healthcare |
Industry | Drug Manufacturers - Specialty & Generic |
Equity Style | Small Cap/Blend |
Next Earnings Release | May. 23, 2024 (est.) |
Last Earnings Release | Jan. 25, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | Dec. 10, 2018 |